March 8, 2010
Genta Announces $25 Million Financing
February 25, 2010
Genta Initiates Once-Weekly Treatment Schedule for Tesetaxel, a Novel Oral Tubulin Inhibitor, in New Dose-Ranging Study
February 10, 2010
Genta Receives $2.8 Million in Non-Dilutive Proceeds from Tax Sale and Designation by EMEA as a Small Business Entity
February 8, 2010
Genta Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanoma
February 2, 2010
Genta Incorporated to Present at the 12th Annual BIO CEO & Investor Conference
January 27, 2010
MEDCI Announces Strategic Alliance with Genta Incorporated to Secure Tesetaxel Licensing Partner
